<DOC>
	<DOCNO>NCT01705847</DOCNO>
	<brief_summary>This study determine appropriate dose regimen GS-9820 subject lymphoid malignancy . This Phase 1b , open-label , dose-escalation expansion study evaluate safety , pharmacokinetics , pharmacodynamics , antitumor activity GS-9820 .</brief_summary>
	<brief_title>A Phase 1b Study Evaluating GS-9820 Subjects With Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Previously treat recurrent Bcell iNHL , DLBCL , MCL , HL CLL Measurable lymphadenopathy Requires therapy Recent history major nonlymphoid malignancy Evidence ongoing infection Concurrent participation another therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>chronic lymphocytic leukemia ( CLL )</keyword>
	<keyword>non-Hodgkin lymphoma ( NHL )</keyword>
	<keyword>Hodgkin lymphoma ( HL )</keyword>
	<keyword>indolent non-Hodgkin lymphoma ( iNHL )</keyword>
	<keyword>diffuse large B-cell lymphoma-activated B-cell ( DLBCL-ABC )</keyword>
	<keyword>DLBCL-germinal center B-cell ( GCB )</keyword>
	<keyword>mantle cell lymphoma ( MCL )</keyword>
	<keyword>GS-9820</keyword>
	<keyword>phosphatidylinositol 3-kinase ( PI3K )</keyword>
</DOC>